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Abstract 
 
Background:  Brain derived neurotrophic factor (BDNF) Val66Met polymorphism 
contributes to development of depression (MDD), but it is unclear whether neural effects 
observed in healthy individuals are sustained in MDD  
 
Aims:  To investigate BDNF Val66Met effects on key regions in MDD neurocircuitry:  
amygdala, anterior cingulate, middle frontal and orbitofrontal regions. 
 
Method:  MRI scans were acquired in 79 MDD (mean age 49 years) and 74 healthy 
volunteers (HV) (mean 50 years).  Effects on surface area and cortical thickness were 
examined with multiple comparison correction.   
 
Results:  Met allele carriers showed reduced caudal middle frontal thickness in both 
MDD and HV. Significant interaction effects were found in the anterior cingulate and 
rostral middle frontal regions in which Met MDD carriers showed the greatest reduction in 
surface area.   
 
Conclusions:  Modulatory effects of the BDNF Val66Met polymorphism on distinct 
subregions in the prefrontal cortex in MDD support the neurotrophin model of 
depression. 
 
Declaration of Interest:  None. 
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Introduction 
 
Heritability estimates in major depressive disorder (MDD) are in the order of 48-75% (1).  
A potential candidate gene is the brain derived neurotrophic factor (BDNF) polymorphism 
which has been linked with an increased incidence of MDD (2).  BDNF is the most 
common of the neurotrophins and has an important role in synaptic plasticity, 
neurogenesis, neural growth and differentiation (3-4).  A common single nucleotide 
polymorphism (SNP) at codon 66 of the BDNF gene results in a valine to methionine 
(Val66Met) substitution which has a functional impact on cellular packaging, 
transportation, and secretion, and the neurotrophic model proposes that decreased 
BDNF expression contributes to the development of depression (5).  BDNF is widely 
distributed within key regions in the neural circuitry of affective processing and in major 
depressive disorder, including in the anterior cingulate, prefrontal regions, hippocampus, 
and amygdala (6).   Effects of the BDNF Val66Met polymorphism in healthy subjects 
though have been variable.  In subcortical limbic regions, reduced volumes of the 
hippocampus (7-8) and amygdala (8) as well as no significant differences (9-10) have 
been reported in Met carriers relative to Val homozygotes.  In prefrontal regions, Met 
carriers have shown reduced middle (MFC) (7,11) and inferior frontal (7) volumes, 
though no significant differences in orbitofrontal (12) volumes.   
 
Few studies have examined the effect of the BDNF polymorphism in depression, and the 
main region of interest to date has been the hippocampus which has shown mixed 
findings with reduced volume in Met carriers (10,13), as well as reduced (14) and 
increased (15) volume in Val homozygotes, while previously we found no differences 
between genotypes (16).  However, studies in depression have been limited in their 
sample characteristics: absence of a healthy control group (13); specified regions of 
interest: namely, hippocampus (10,14-16) and amygdala (10); and measures of white 
matter tracts only (17-18).  Moreover, the majority of studies have measured regional 
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gray matter, including gray matter density.  The determinants of the gray matter volume 
of a given cortical region are the surface area and cortical thickness, which have distinct 
developmental and genetic origins (19).  Volumetric alterations are thus a product of 
independent or concurrent disparities in the two constituents.  In healthy subjects, Yang 
et al. (20) found a broad distribution of reduced cortical thickness in Met homozygotes 
compared to Val homozygotes in Chinese adults.  To our knowledge, BDNF Val66Met 
modulation of cortical thickness and surface area has not been investigated in MDD.   
 
We sought to examine the effects of the BDNF Val66Met polymorphism on the 
neurocircuitry of depression, in particular the amygdala and the prefrontal regions of the 
anterior cingulate (ACC), middle frontal and orbitofrontal cortices.  We investigated the 
modulatory effects on regional brain volume and its components of surface area and 
cortical thickness.  We expected to observe an effect of Met carrier status in reduced 
cortical volume in the middle frontal cortices (7,11) and perhaps in the corresponding 
cortical thickness (20) in healthy subjects, while it was uncertain whether the impact of 
the polymorphism would be sustained in MDD. 
 
Method 
 
The study was approved by the Ethics Research Committee, Institute of Psychiatry, 
King’s College London, UK, and all participants provided written informed consent. All 
participants had previously participated in genetic association studies (21) and were of 
white European ancestry.  A total of 153 subjects were included: 79 patients with a 
diagnosis of recurrent major depressive disorder (MDD) and 74 healthy controls (HC) 
matched by age, sex, handedness and IQ (Table 1).  All MDD patients met criteria for 
recurrent MDD as characterised by the DSM-IV-TR using the Schedules for Clinical 
Assessment in Neuropsychiatry interview (22), and healthy controls were screened to 
ensure they had never experienced a depressive episode.  All participants were 
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screened for contraindications to MRI, as well as any indication of neurological disorder 
such as head injury leading to loss of consciousness or conditions known to effect brain 
structure, such as alcohol or drug abuse.  Subjects were excluded if they or a first 
degree relative had ever experienced an episode of mania, hypomania, schizophrenia or 
mood incongruent psychosis.  IQ was measured using the Wechsler Abbreviated Scale 
of Intelligence (23) and depressive symptoms with the Beck Depression Inventory (24).   
 
Most patients were taking at least one antidepressant medication (n=58), and some were 
not taking any medications at the time of the MRI scan (n=21) (Table 2). The 
antidepressant medications encompassed selective serotonin reuptake inhibitors, 
serotonin-noradrenergic reuptake inhibitors, tricyclic antidepressants, and other 
antidepressant classes. In addition, 7 patients were taking additional medication for 
augmentation of the antidepressant medication: mood stabilisers, benzodiazepine, 
antipsychotic medication, and thyroxine.   
 
Genotyping 
 
Val66Met BDNF genotyping was performed using Taqman 5’ exonuclease assay (16).  
BDNF genotypes were divided into three groups: Val/Val, Val/Met and Met/Met.  For the 
purpose of the present analysis, the groups were combined into Val homozygotes 
(Val/Val) and Met carrier (Met-allele) groups due to the small number of Met 
homozygotes subjects.   
 
MRI data acquisition 
 
Magnetisation-Prepared Rapid Gradient Echo (MP-RAGE) T1-weighted scans were 
acquired at 1.5T (General Electric, WI, USA) with the parameters: TE = 3.8 ms, TR = 
8.59 ms, flip angle = 8, field of view = 24 × 24 cm, slice thickness = 1.2 mm, number of 
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slices = 180 and image matrix = 256 × 256.  The MPRAGE volume was acquired using 
the ADNI custom pulse sequence, with full brain and skull coverage (25). 
 
Data analysis 
 
Gray matter volumes, surface area and average cortical thickness measurements were 
measured using the Freesurfer pipeline version 5.1.0 (http:// surfer.nmr.mgh.harvard. 
edu/).  The analysis involved removal of non-brain tissue using a hybrid 
watershed/surface deformation procedure, automated Talairach transformation, 
segmentation of the subcortical white matter and deep grey matter volumetric structures, 
intensity normalization, tessellation of the grey matter-white matter boundary, automated 
topology correction, and surface deformation following intensity gradients to optimally 
place the grey/white and grey/cerebrospinal fluid borders at the location where the 
greatest shift in intensity defines the transition to the other tissue class.   Once the 
cortical models are complete, registration to a spherical atlas takes place which utilizes 
individual cortical folding patterns to match cortical geometry across subjects. This is 
followed by parcellation of the cerebral cortex into units based on gyral and sulcal 
structures. The pipeline generated 68 cortical thickness, cortical volume, surface area, 
mean curvature, gaussian curvature, folding index and curvature index measures (34 
from each hemisphere) and 46 regional subcortical volumes.  All volumetric measures 
from each subject were normalized by the subject’s intracranial volume, while cortical 
thickness measures were not normalized.   
 
As a priori hypotheses, only the following regions were examined: amygdala, anterior 
cingulate (rostral and caudal ACC), middle frontal cortex (rostral and caudal), and 
orbitofrontal cortex (medial and lateral) bilaterally.  A multivariate ANOVA (SPSS version 
21) was used to assess differences between both MDD patients and healthy controls 
and between Val homozygotes and Met carriers (Val/Met and Met/Met genotypes). False 
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discovery rate (FDR) was used to adjust for multiple comparisons resulting from the 
ANOVA models with alpha = 0.05 (26). 
 
Results 
 
A significant effect of genotype which survived FDR correction for multiple comparisons 
was found in the left caudal middle frontal cortex (Brodmann’s area (BA) 6) in cortical 
thickness in which Met carriers showed the greatest reduction in cortical thickness as 
compared to Val homozygotes in both the MDD and healthy control groups (Val/Val 
MDD: 2.474 (0.138) mm; Met-allele MDD: 2.434 (0.177) mm; Val/Val HC: 2.491 (0.158) 
mm; Met-allele HC: 2.361 (0.141) mm (F (1, 149) = 11.029, p = 0.001)) (Figure 1).   
 
Significant interaction effects which survived multiple comparison correction were found 
in the surface area in 3 regions: right caudal anterior cingulate (Val/Val MDD: 782.48 
(140.172) mm2; Met-allele MDD: 711.00 (150.610) mm2; Val/Val HC: 764.02 (153.134) 
mm2; Met-allele HC: 869.26 (186.699) mm2, (F (1, 149) = 11.729, p = 0.001)); right 
rostral middle frontal cortex ((Val/Val MDD: 5975.30 (667.014) mm2; Met-allele MDD: 
5592.39 (611.784) mm2; Val/Val HC: 5673.02 (754.373) mm2; Met-allele HC: 6125.70 
(671.124) mm2 ,(F (1, 149) = 13.489, p = 0.0003)); and left rostral middle frontal cortex 
((Val/Val MDD: 5723.28 (633.790) mm2; Met-allele MDD: 5383.06 (473.553) mm2; 
Val/Val HC: 5477.19 (677.134) mm2; Met-allele HC: 5890.04 (711.311) mm2, (F (1, 149) 
= 12.869, p = 0.0005)).  In all of these regions, reduced surface area was associated 
with Met carrier status relative to Val homozygotes in MDD, while the inverse was 
observed in healthy subjects. 
 
No other main or interaction effects remained significant following multiple comparison 
correction, including in the amygdala (MDD left amygdala: 1385.24 (219.404) mm3, MDD 
right: 1482.92 (231.585) mm3; HC left: 1433.81 (257.164) mm3, HC right: 1552.50 
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(271.312) mm3; Val/Val left: 1432.30 (249.516) mm3, Val/Val right: 1537.49 (250.534) 
mm3, Met-allele left: 1372.20 (218.359) mm3, Met-allele right: 1484.20 (255.904) (all p > 
0.3).   
 
Discussion 
 
Modulatory effects of the BDNF Val66Met polymorphism as well as genotype by MDD 
interactions were revealed in key nodes in the neurocircuitry of MDD.  Distinct effects 
were observed in the anterior cingulate and subregions of the middle frontal cortices 
implicating converging yet separate influences of the disease process, genetic 
modulation, and their interaction.   
 
Pezawas et al. (7) provided the first report of an effect of the BDNF Val66Met 
polymorphism in the caudal middle frontal cortex, revealing reduced gray matter volume 
in healthy Met carriers compared to Val homozygotes.  The potential contribution of 
cortical thinning to the volumetric reductions has recently been added (20), and reduced 
middle frontal activity has also been observed (9) in healthy Met carriers.  In the present 
study, we found a main effect of Met carrier status on cortical thinning in the caudal 
middle frontal cortex in both healthy subjects and in patients with depression.  Our study 
extends both the observation by Yang et al. (20) in healthy Chinese adults and the 
original finding (7) by localising the contribution of cortical thinning to the reductions in 
caudal middle frontal volume.   
 
Moreover, this is the first report of the extent that Met carrier status leads to middle 
frontal cortical thinning as the effect of the Met allele appears to supersede the disease 
process effects of MDD on cortical thickness.  Gray matter reductions in the caudal 
middle frontal region have been frequently observed in MDD, which show further 
reductions in recurrent MDD (27).  Our findings indicate that the impact of the BDNF 
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Val66Met polymorphism on cortical thinning in the caudal middle frontal region is even 
greater than that of recurrent MDD.  It is possible that the influence of the Met allele in 
this region may not necessarily be causal in itself for MDD, but may be a predisposing, 
contributory factor in association with other neurogenic effects.  Stress is linked an 
increase in cortisol, which in turn causes a reduction of BDNF (28).  Met carriers are less 
able to compensate to this BDNF reduction due to the deficient transport of the BDNF 
preprotein which causes clumping around the nucleus, perhaps leading to neuronal 
atrophy in response the reduced BDNF levels (4-5).   
 
We also observed a significant interaction effect in the surface area in the caudal anterior 
cingulate and rostral middle frontal cortices.  The anterior cingulate and middle frontal 
cortices are key regions in the neurocircuitry of mood disorders, and the anterior 
cingulate is a well replicated predictive marker of clinical response in MDD (29) which is 
evident at the individual level (30).  Surface area and cortical thickness have 
independent genetic and developmental origins (19).  The radial unit hypothesis 
proposes that cortical thickness is determined by the number of cells within a neuronal 
column and cortical surface area is comprised of the number of neuronal columns (31).  
There is support for a general regional expansion of surface area from childhood into 
adolescence, particularly in boys (32), followed by subsequent decreases in adulthood 
with increasing age (33), while cortical thinning is a pronounced feature of adolescence 
which continues into adulthood (32).  There is though some notable variability in the 
regional changes (32-33), for example the surface area of the anterior cingulate cortex 
may show relatively fewer changes in adulthood (32).  Modulation of grey matter density 
by the BDNF Val66Met polymorphism in both the anterior cingulate and middle frontal 
cortices has been found in bipolar disorder (34), in the anterior cingulate in healthy 
subjects with a history of childhood abuse (12), while no prefrontal regional effects have 
been reported in schizophrenia (35).  The present study localises the genetic influence to 
cortical surface area in its contribution to grey matter volume, which had not been 
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examined in previous studies in patient populations (34-35).  It is possible that the 
surface area reductions observed in the present study is an endophenotype for MDD, or 
more generally for mood disorders including bipolar disorder, or it may also be a feature 
in schizophrenia which has not been well captured by the morphometric studies to date.  
The lack of an association of the BDNF gene with schizophrenia (36) though suggests 
that the effect may be more strongly expressed in mood disorders.   
 
Contrary to our hypothesis, no significant interaction effects were found in the grey 
matter volume of the amygdala.  Our observations are consistent with findings in healthy 
BDNF Met carriers with a history of childhood adversity (12) and in depression (10), but 
there have also been reports of reduced amygdala volume in healthy subjects with (37) 
and without (8) a history of stressful events.  Similarly, studies of amygdala responsivity 
have been mixed with reports of significant (38-39) but more frequently of no impact 
(9,40-41) of the BDNF polymorphism.  The literature on amygdala volume in depression 
though is inconsistent with some suggestion that amygdala volume is reduced in more 
chronic forms of depression (42).  In the present study, patients had a history of 
recurrent depression characterised by discrete acute depressive episodes with periods 
of euthymia rather than a more chronic treatment resistant type of depression.  Our 
findings are most comparable with Frodl et al. (10) who similarly did not observe any 
effects of diagnosis or BDNF genotype on amygdala volume.   
 
We had limited our analysis to a priori defined regions in the prefrontal cortex and the 
amygdala within the neurocircuitry of depression.  However, the sample size in the 
present study is relatively modest and replication in an independent sample is required.  
Cortical thinning in the medial orbitofrontal region has been reported in first episode 
depression (46) and in a younger cohort of MDD patients (mean age 34 years) than in 
the present study (47).  Although there was evidence of left medial orbitofrontal cortical 
thinning in MDD patients relative to healthy controls in the current sample, this difference 
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did not survive correction for multiple comparisons.   Furthermore, BDNF Val66Met 
effects have also been observed in the temporal and parietal cortices in healthy Chinese 
adults (20).  There may also be a modulatory effect of early life stress as healthy Met 
carriers with a history of greater stressful events have shown reduced grey matter 
volume in the amygdala (37), hippocampus (37) and anterior cingulate cortex (12) as 
compared to Val homozygotes.  Another limitation of the present study is the absence of 
data on the history of possible childhood trauma in our subjects, though it is unclear 
whether these effects would persist alongside the pathophysiological effects of the 
illness.  As well, most of the patients were taking antidepressant medication, which may 
have an effect on BDNF levels (5) and in turn potentially on neural volumes (43).  The 
anterior cingulate region has been consistently identified as a predictive marker of 
clinical response (29), and the BDNF polymorphism has shown an association with 
treatment response (44).  Furthermore, an interaction effect of BDNF and its high-affinity 
receptor, neurotrophic tyrosine kinase receptor 2 (NTRK2 ), gene polymorphisms has 
been associated with the development of treatment-resistant depression (45).  How 
these potentially complementary markers may interact at a neural level in predicting 
clinical response requires further investigation.  Neural correlates of BDNF associations 
with clinical response in a patient sample which is medication free and perhaps in their 
first episode of depression would elucidate the effects of medication, recurrent episodes 
of depression, and prediction of clinical response. 
 
In summary, the present study demonstrated sustained effects of the BDNF Val66Met 
polymorphism on distinct subregions in the prefrontal cortex in depression.  The effects 
in the caudal middle frontal regions exceeded those of the illness as Met carrier status 
was associated with greater cortical thinning in both MDD and healthy subjects.  Effects 
in the anterior cingulate and rostral middle frontal regions revealed an interaction with 
BDNF Val66Met genotype, in which MDD Met carriers showed the greatest reduction in 
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surface area.  Our findings specify the anterior cingulate and middle frontal regions as 
key regions within the neurotrophin hypothesis of depression.   
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Figure Legends 
 
Figure 1. 
A significant main effect of BDNF Val66Met polymorphism which survived correction for 
multiple comparisons was found in the left caudal middle frontal region (Brodmann’s area 
6).  Met allele carriers showed the greatest reduction in cortical thickness in both the 
MDD and healthy subject groups.  Units are mm. Boxplots indicate interquartile range, 
median, and range.  For Met carriers, the boxes are colored in green with diagonal lines 
and Val homozygotes are colored in blue with horizontal lines. 
 
Figure 2. 
The significant interaction effect in the right caudal anterior cingulate is presented.  Met 
carriers with depression showed the greatest reduction in surface area as compared to 
MDD and healthy Val homozygotes as well as healthy Met carriers.  Units are mm2. 
Boxplots indicate interquartile range, median, and range.  For Met carriers, the boxes are 
colored in green with diagonal lines and Val homozygotes are colored in blue with 
horizontal lines.  
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Table 1.  Demographic Features 
 
MDD  
(n = 79) 
Healthy Controls 
(n = 74) 
Test statistic 
Age (years) 49.09 (8.96)  50.92 (7.82)  F=1.803, p=0.181 
Gender 27 M: 52 F 34 M: 40 F ²= 2.207, p=0.137 
Verbal IQ 117.44 (11.59) 119.04 (8.74) F=0.917, p=0.340 
Handedness  69 R: 8 L 63 R: 10 L ²= 0.390, p=0.823 
BDNF 
Met carriers 
Val/Val 
 
33 
46 
 
27 
47 
 
²= 0.448, p=0.503 
 
Mean values are presented with standard deviation in parenthesis.  Abbreviations: MDD, 
Major Depressive Disorder; M, male; F, female; R, right handed; L, left handed. One 
subject in each group was ambidextrous, and data were missing from one subject in the 
MDD group.  
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Table 2.  Clinical Features of MDD Participants 
 MDD  
 
Met-carrier 
(n = 33) 
Val/Val 
(n = 46) 
BDI 15.64 (11.58) 15.61 (11.10) 
STAI 39.2 (11.07) 38.58 (10.15) 
Age of onset (years) 20.28 (9.54) 20.30 (9.67) 
Number of previous episodes 4.41 (3.16) 4.18 (3.24) 
History of suicide attempts  14 (42.4%) 19 (41.3%) 
History of ECT  2 (6.1%) 4 (8.7%) 
History of hospital admissions 9 (27.3%) 13 (28.3%) 
Current antidepressant medication 26 (78.8%) 32 (69.6%) 
 
Mean values and parentheses present the standard deviation or percentages as 
indicated.  Mean number of MDD subjects are presented for number of previous 
episode, clinical history, and current medications. Abbreviations:  MDD, Major 
Depressive Disorder; BDI, Beck Depression Inventory; STAI, State Trait Anxiety 
Inventory. There were no significant differences between the MDD Met-carriers and 
Val/Val homozygotes in any of the measures.  
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